Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03746847 · ClinicalTrials.gov registry record
PET Imaging in Patients With Suspected Cardiac Sarcoidosis
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 20
- Enrollment target
NCT03746847: Completed study, sponsored by University of Pennsylvania.
NCT03746847 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03746847 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
Gallium-68 DOTATATE is a radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body, which is approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors. The study will see how the tracer is taken up in your heart before and after treatment using an imaging scan called Positron Emission Tomography / Computed Tomography (PET/CT). Investigators are doing this research study to find out if DOTATATE can help doctors diagnose people with cardiac (heart) sarcoidosis better as well as serve as a follow-up monitoring tool for a response to therapy.
Interventions
- DRUG Gallium-68 DOTATATE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2018-12-01 |
| Est. Completion | 2022-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03746847
The ClinicalTrials.gov registry entry for NCT03746847 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gallium-68 DOTATATE is the first listed.
NCT03746847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03746847 about?
NCT03746847 is a clinical study titled "PET Imaging in Patients With Suspected Cardiac Sarcoidosis". Gallium-68 DOTATATE is a radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body, which is approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors. The study will see how the tracer is taken up in your heart before and a...
What is the current status of trial NCT03746847?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2018-12-01. Estimated completion is 2022-12-01.
What interventions are being tested in trial NCT03746847?
The interventions under investigation include: Gallium-68 DOTATATE (DRUG).
Who is sponsoring clinical trial NCT03746847?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.